Comparison of Contrast-enhanced Spectral Mammography (CESM) to MRI in Screening High Risk Women for Breast Cancer

Description

This research study is comparing Dual-Energy Contrast-Enhanced Spectral Mammography (CESM) to MRI as a screening tool for breast cancer.

Study Start Date

November 2014

Estimated Completion Date

January 2021

Interventions

  • Other: CESM
  • Other: MRI

Specialties

  • Obstetrics & Gynecology: Breast
  • Oncology: Breast,Diagnostics/Radiology
  • Radiology: MRI
  • Physician Assistant: Hematology/Oncology,Obstetrics/Gynecology,Radiology

MeSH Terms

  • Breast Cancer
  • Breast Neoplasms
  • MRI

Study ID

Dana-Farber Cancer Institute -- 14-225

Status

Recruiting

Trial ID

NCT02275871

Study Type

Interventional

Trial Phase

N/A

Enrollment Quota

220

Sponsor

Dana-Farber Cancer Institute

Inclusion Criteria

  • Women
  • Age > or equal to 30 years
  • High risk (>20% lifetime risk)
  • Has a bilateral mammogram within the last 7 months
  • Has had a same day high risk screening MRI

Exclusion Criteria

  • Participants who have a known allergy or contraindication to iodinated contrast.
  • Participants who have a known allergy to food or medications.
  • Participants who have renal insufficiency or failure.
  • Participants who are pregnant or breastfeeding.
  • Participants with a concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia.

Gender

Female

Ages

30 Years and older

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Study Locations and Contact Information (1)

Study Location Distance Name Phone Email
Beth Israel Deaconess Medical Center - Boston, Massachusetts 2.4 miles Jordana Phillips MD 617-667-1630 jphilli2@bidmc.harvard.edu

ClinicalTrialsLocator.com provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from ClinicalTrials.gov. This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.